Navigation Links
ISPE Announces FDA to Co-Sponsor June CGMP Conference in Baltimore
Date:3/14/2012

TAMPA, Fla., March 14, 2012 /PRNewswire-USNewswire/ -- ISPE announced today the Food and Drug Administration (FDA) will co-sponsor the upcoming "Redefining the 'C' in 'CGMP'" Conference in Baltimore, Md. USA on 4 – 5 June 2012. The conference is the first joint ISPE-FDA conference focused on CGMP issues.

(Logo: http://photos.prnewswire.com/prnh/20120208/DC49497LOGO)

The conference will feature a new format with a number of audience-participation and interactive sessions. A Hot Topic Discussion Forum between attendees and regulators will feature discussion on critical industry issues, concerns and collaboration. A mixed panel of FDA and industry leaders will also answer the industry's most pressing questions during a moderated "Meet the Press" session. Topical plenary and education sessions will be featured throughout the two-day event.

"This first annual co-sponsored conference reflects ISPE's commitment to engaging its Members, companies and global regulatory agencies in dialog around critical problem-solving and learning," said ISPE's president and CEO Nancy Berg. "As the independent pharmaceutical manufacturing association, ISPE is dedicated to strengthening industry through relevant technical education, training and networking. This new conference hits the mark, assembling the entire supply chain to discuss industry's commitment to identifying and adopting quality and manufacturing techniques that continue to deliver a safe, consistent and available drug supply."

"FDA is very excited to be working on this joint conference," said Steven Lynn, Acting Director, FDA/CDER/Office of Compliance/ Office of Manufacturing and Product Quality (OMPQ). "Our goal is to make this a highly collaborative Agency and Industry conference, where we can come together to discuss the current and future state of CGMPs in the quest to e
'/>"/>

SOURCE ISPE
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 30, 2015  Astellas today announced topline results ... efficacy and safety of intravenous (IV) and oral ... development for adults with candidemia and other invasive ... demonstrated that the trial did not meet its ... in isavuconazole-treated patients at the end of IV ...
(Date:7/29/2015)... July 29, 2015 Insulet Corporation (NASDAQ: PODD ... its OmniPod ® Insulin Management System, today announced ... 30, 2015. The Company also announced that it will ... results and conference call from Thursday, July 30, as ... Revenue Highlights: , Preliminary second ...
(Date:7/29/2015)...  UBM Canon brings MEDevice San Diego Conference & ... on September 1-2, 2015, with a multi-track conference program ... Business Development track will be a panel on How ... featuring Renee Ryan , Vice President of Venture ... , Partner, Canaan Partners; and Jordan Kramer , ...
Breaking Medicine Technology:Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 2Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 3Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 4Astellas Provides Update on Phase 3 Study Evaluating Isavuconazole in Patients with Candidemia and Other Invasive Candida Infections 5Insulet Reports Preliminary Second Quarter 2015 Revenue Results 2Insulet Reports Preliminary Second Quarter 2015 Revenue Results 3Insulet Reports Preliminary Second Quarter 2015 Revenue Results 4Insulet Reports Preliminary Second Quarter 2015 Revenue Results 5MEDevice San Diego Offers Tips on Securing Financial Backing from Investors 2
... PXS; Nasdaq: PXSL) today announced that the company ... reached agreement on the phase 3,registration trial of ... The SPA process allows for FDA evaluation ... primary basis of an efficacy claim in support ...
... 19 The Australian company Fermiscan,who is using ... new breast cancer,screening test through the analysis of ... 69% in detecting breast cancer., (Photo: ... the Journal of the American Medical,Association(1) (US study), ...
Cached Medicine Technology:Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial 2Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial 3New Australian Technology: Detecting Breast Cancer With Hair 2New Australian Technology: Detecting Breast Cancer With Hair 3New Australian Technology: Detecting Breast Cancer With Hair 4
(Date:7/30/2015)... ... ... Bird B Gone, the leader in bird control products for commercial, industrial ... birds from the AC units and ventilation systems on hospital roofs. Bird droppings can ... Nile virus. When these droppings dry, the fine powder can be carried into hospitals ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... at multinational organizations and NGO’s, according to a new survey by leading international ... that property damage and employee medical expenses represented the largest sources of financial ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... After a ... Argus II retinal implant, more commonly known as the “bionic eye,” researchers have determined ... safe and viable tool for patients facing or already affected by complete vision loss ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... are living longer and do not find a complete removable denture acceptable. The ... of care. The practices that incorporate less expensive, immediate loading techniques will have ...
(Date:7/30/2015)... Orem, UT (PRWEB) , ... July 30, 2015 , ... When trying to gain weight, many people place a lot ... the amount of calories that need to be consumed. However, another key component to successful ... to gain weight. To assist with this, CB-1 Weight Gainer gives three tips on ...
Breaking Medicine News(10 mins):Health News:Bird B Gone’s New Bird Hazing System Keeps Disease-Carrying Bird Droppings Out of Hospitals 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 3Health News:The Vision Enhancing “Bionic Eye” Deemed Safe For Long Term Use After Three Year Clinical Trial 2Health News:Chicago Implant Dentist/Implantologist Dr. Irfan Atcha Speaks to Local Dentists about Advances in Dental Implants in August. 2Health News:Chicago Implant Dentist/Implantologist Dr. Irfan Atcha Speaks to Local Dentists about Advances in Dental Implants in August. 3Health News:CB-1 Weight Gainer Gives Three Tips on When to Eat to Gain Weight 2Health News:CB-1 Weight Gainer Gives Three Tips on When to Eat to Gain Weight 3
... fatty acids may be unwise for those with weakened immunity.,Researchers ... for many years now and know that one of their ... - rich in omega-3s - often benefit those with arthritis, ... response is a key component of the immune system in ...
... the September 11 terrorist acts in New York and ... put on hold for several days, which severely affected ... are shipped via air due to their specific nature. ... pharmaceuticals with a radioactive component, and are used in ...
... study of middle-aged women suggests that those who eat the ... wide variety of foods. The Healthy Eating Index (HEI) is ... quality of someone's diet. This emphasises your eating pattern rather ... ten for servings of grains, vegetables, fruit, milk or meat, ...
... The balance of fats and oils in your diet can ... degeneration (AMD) is a currently untreatable disease of the eye ... suggests, it gets worse with age and diet has been ... Massachusetts Eye and Ear Infirmary carried out a study of ...
... not help the sickest patients, according to the latest ... the alveoli - are progressively destroyed, leaving the patient ... activities like climbing stairs or carrying their shopping. In ... surgery was beneficial for people with emphysema. It appeared ...
... The Food and Drug Administration has few details about ... are needed to protect both foreign patients taking experimental ... results. ,The number of pharmaceutical researchers working outside ... the FDA increased 16-fold from 1990 to 1999, dwarfing ...
Cached Medicine News:
... of any biological activity but appears to ... of insulin. Although insulin and C-Peptide are ... fasting levels of C-Peptide are 5-10 fold ... the longer half-life of C-Peptide. The glucagon ...
... The Array Multifocal IOL was designed ... with independence from glasses in most situations. ... IOL is similar to that of a ... usually much better and about 19 in ...
Inquire...
... IgG Enzymelinked Immunosorbent Assays(ELISA) is intended for ... antibody to Measles Rubeola) virus in human ... for the determination of immune status. Paired ... demonstrate seroconversion or a significant rise in ...
Medicine Products: